Dr. David Michael Joyce, MD

Dr. Joyce practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Joyce's NPI, 1184893190, was assigned on February 23, 2008. Dr. Joyce graduated from Cleveland Medical College, Homeopathic in 2007. Dr. Joyce holds Florida license ME124660.

Dr. Joyce's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Joyce's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Joyce is also affiliated with BayCare St. Joseph's Hospital. The medical group on file is Ability Rehabilitation. Dmand AI also links Dr. Joyce to 3 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Joyce practices, 8 sites in all. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Joyce's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dr. Joyce is board certified in orthopaedic surgery by the American Board of Orthopaedic Surgery. Dmand AI has Dr. Joyce's licenses on file in 3 states: Florida, Ohio and Tennessee.

Dmand AI lists arm, wrist, hand fracture and dislocation, arthritis, hip replacement, joint or bone infection, joint pain, knee replacement, lower back pain and orthopedic surgery of arms and legs among the conditions Dr. Joyce treats.

CMS data shows 313 Medicare services from Dr. Joyce across 5 procedure codes in 2024, for 195 Medicare patients. Medicare paid $21,025 for them.

CMS counts 195 Medicare patients who saw Dr. Joyce in 2024. The largest group is 65 to 74, with 95 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 2.41, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Joyce's median patient age at 65, with 54% women.

In 2024, Dr. Joyce wrote 70 Medicare Part D claims for 32 patients. 97% of them were for generic drugs. CMS names the drug for 32 of them, across 2 drugs with 11 or more claims each, at $653 in total drug cost. In 2023, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Joyce for performance year 2024, reported as part of a group. Dr. Joyce accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Joyce as offering telehealth. CMS counts 16 procedures of removal of tissue by Dr. Joyce, more than 67% of the clinicians it reports for that procedure.

Knee replacement: 1 to 10 procedures (CMS shows small counts as a range)

Spinal fusion: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 30 papers to Dr. Joyce, published from 2015 to 2025. 2023 was the busiest year, with 5. The most frequent topics are Reoperation, Bone Neoplasms and Osteosarcoma. Dr. Joyce has published most often in Radiol Case Rep. Dr. Joyce's most frequent co-authors are David M. Joyce, DO, Evita B. Henderson-Jackson, MD and John E. Mullinax, MD.

CMS Open Payments shows 65 general payments to Dr. Joyce from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 59% of the total. Stryker Corporation paid the most, $6,808.

Dr. Joyce graduated from Cleveland Medical College, Homeopathic in 2007.

Dr. Joyce is in network with 10 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.